Organ Dysfunction in Metabolic-Associated Fatty Liver Disease: Effect of Cofactors

Guest Editors:

Kusum K. Kharbanda, PhD
Department of Internal Medicine, University Nebraska Medical Center, Veteran Affairs Medical Center, Omaha, NE, USA.

Ashwani K. Singal, MD
Sanford School of Medicine, University of South Dakota, Vermillion, SD, USA.

Amedeo Lonardo, MD
Department of Internal Medicine, Ospedale Civile di Baggiovara, 1135 Via Giardini, Modena, Italy.

Natalia A. Osna, MD, PhD
Department of Internal Medicine, University of Nebraska Medical Center, Veteran Affairs Medical Center, Omaha, NE, USA.

Special Issue Introduction:

Nonalcoholic fatty liver disease (NAFLD), now tendentially renamed MAFLD (metabolic-associated fatty liver disease), is a systemic metabolic disorder that encompasses a clinico-pathological spectrum ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma.

NAFLD and NASH are pathogenically associated with gut dysbiosis, sarcopenia and expanded, dysfunctional adipose tissue. Clinically, extra-hepatic manifestations, notably either the full-blown metabolic syndrome or its individual components and cardio-nephro-vascular complications, are major features of MAFLD and dictate the disease course.

This thematic special issue highlights metabolic syndrome co-factors, including but not limited to alcohol, diet, immune surveillance, infection, genetics, epifactors and sedentary behavior, which affect liver disease progression and also induce dysfunction in other target organs and organ systems such as gastrointestinal, cardiovascular, adipose, muscle, kidneys and pancreas.

Original research, review articles, and short communications on the role of co-factors exacerbating organ dysfunction in MAFLD are welcome to this topical special issue.

Benefits to Authors:

- The APCs ($600) will be WAIVED;
- Enjoy faster publication than regular submissions;
- Authors will be invited as Guest Speakers to our journal webinars. The webinar will be held via Zoom and it will also be broadcast live on Youtube and the Chinese WeChat Official Account, Video Account, Bilibili;
- A special interview will be provided to authors and will be promoted on the journal homepage and all media promotion platforms of both via the journal and publisher;
- Winner(s) of the "Best Paper Award" will be awarded. The reward will be in the form of a cash prize and a certificate.
Journal Introduction:

Metabolism and Target Organ Damage (M&TOD, https://mtodjournal.net/, ISSN: 2769-6375) is a journal newly launched in 2021 with fast development in the past few months. It is an international, peer-reviewed, open access interdisciplinary journal which provides an online platform for the publication of clinical, basic, and translational studies. It covers (cardio)-metabolic disorders per se, such as obesity, diabetes, dyslipidemias, arterial hypertension and hyperuricemia in all age groups.

Editorial Board team:

Scan the QR code to view the journal website